Richard S. Finn

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 7.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.4K citations · Full text

Medicine, Oncology, Pharmacology +12

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Jorge A. Marrero, Laura Kulik, Claude B. Sirlin et al. · Hepatology · 2018 · 4.6K citations · Full text

Medicine, Internal Medicine, Oncology +17

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K. Heimbach, Laura Kulik, Richard S. Finn et al. · Hepatology · 2017 · 4.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix, Shukui Qin, Philippe Merle et al. · The Lancet · 2016 · 3.7K citations · Full text

Medicine, Oncology, Pharmacology +8